Dyadic International (DYAI) EBIT (2018 - 2026)
Dyadic International (DYAI) posted EBIT of -$1.9 million for Q1 2026, down 23.88% sequentially from -$1.5 million in Q4 2025, and up 4.98% YoY from -$1.8 million in Q1 2025.
Dyadic International (DYAI) EBIT (2018 - 2026) Analysis & Trends
Dyadic International has reported EBIT for 9 years, with the latest figure at -$1.9 million in Q1 2026.
- Quarterly EBIT rose 4.98% year-over-year to -$1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.1 million (down 22.76% YoY) and the FY2025 annual result came in at -$7.2 million, down 21.9% from the prior year.
- EBIT retreated to -$1.9 million in Q1 2026 per DYAI's latest filing, from -$1.5 million in the prior quarter.
- Over five years, EBIT peaked at -$202614.0 in Q3 2024 and troughed at -$3.3 million in Q2 2022.
- A 5-year average of -$2.0 million and a median of -$2.0 million in 2025 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2025: EBIT jumped 99.92% in 2022, then plunged 850.26% in 2025.
- Over 5 years, EBIT stood at -$2.2 million in 2022, then advanced by 3.16% to -$2.2 million in 2023, then increased by 29.45% to -$1.5 million in 2024, then fell by 0.38% to -$1.5 million in 2025, then dropped by 23.88% to -$1.9 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$1.9 million, -$1.5 million, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Dyadic International | 20.18 Mn | 20.18 Mn | - | -1.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.90 Mn |
| Dec 31, 2025 | -1.54 Mn |
| Sep 30, 2025 | -1.93 Mn |
| Jun 30, 2025 | -1.73 Mn |
| Mar 31, 2025 | -2.00 Mn |
| Dec 31, 2024 | -1.53 Mn |
| Sep 30, 2024 | -202,614.00 |
| Jun 30, 2024 | -2.04 Mn |
| Mar 31, 2024 | -2.13 Mn |
| Dec 31, 2023 | -2.17 Mn |
| Sep 30, 2023 | -1.72 Mn |
| Jun 30, 2023 | -2.29 Mn |
| Mar 31, 2023 | -2.05 Mn |
| Dec 31, 2022 | -2.24 Mn |
| Sep 30, 2022 | -1.86 Mn |
| Jun 30, 2022 | -3.32 Mn |
| Mar 31, 2022 | -2.74 Mn |
| Dec 31, 2021 | -4.22 Mn |
| Sep 30, 2021 | -3.32 Mn |
| Jun 30, 2021 | -3.87 Mn |